Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Connect  >  Sino Biopharmaceutical Limited    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Connect
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
11.76 11.52 11.56 11.46 11.28 Last
18470600 27041500 36438700 30186540 36367640 Volume
-0.17% -2.04% +0.35% -0.87% -1.57% Change
Financials (HKD)
Sales 2019 28 088 M
EBIT 2019 6 189 M
Net income 2019 3 625 M
Finance 2019 7 160 M
Yield 2019 0,63%
Sales 2020 31 532 M
EBIT 2020 7 103 M
Net income 2020 4 186 M
Finance 2020 10 768 M
Yield 2020 0,73%
P/E ratio 2019 39,6x
P/E ratio 2020 34,1x
EV / Sales2019 4,79x
EV / Sales2020 4,15x
Capitalization 142 B
More Financials
Company
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of ophthalmia and hepatitis. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs... 
Sector
Pharmaceuticals
Calendar
03/25Earnings Release
More about the company
Surperformance© ratings of Sino Biopharmaceutical Lim
Trading Rating : Investor Rating :
More Ratings
Latest news on SINO BIOPHARMACEUTICAL LIM
02/20SINO BIOPHARMACEUTICAL : Voluntary announcement - application for new indication..
PU
02/17SINO BIOPHARMACEUTICAL : Completion of the issue of euro750,000,000 zero coupon ..
PU
02/17NOTICE OF LISTING ON THE STOCK EXCHA : 40150)
PU
02/15SINO BIOPHARMACEUTICAL : Convalescent plasma offers promising treatment for coro..
AQ
02/10SINO BIOPHARMACEUTICAL : VOLUNTARY ANNOUNCEMENT - "FULVESTRANT INJECTION" OBTAIN..
PU
02/03SINO BIOPHARMACEUTICAL : Voluntary announcement - investigational new drug appli..
PU
01/22Sino Biopharmaceutical Seeks to Raise EUR750 Million via Bonds to Fund R&D, F..
DJ
01/20SHANGHAI HENLIUS BIOTECH : Asia-Pacific has a Record Year for Clinical Trials, a..
AQ
01/13SINO BIOPHARMACEUTICAL : Ambrx and Sino Biopharma Announce Collaboration to Deve..
PR
2019SINO BIOPHARMACEUTICAL : Voluntary announcement - "ticagrelor tablet" obtains ap..
PU
2019SINO BIOPHARMACEUTICAL : Voluntary announcement - "bortezomib for injection" obt..
PU
2019SINO BIOPHARMACEUTICAL : Voluntary announcement- "argatroban injection" obtains ..
PU
2019SINO BIOPHARMACEUTICAL : Voluntary announcement - "bendamustine hydrochloride fo..
PU
2019SINO BIOPHARMACEUTICAL : Voluntary announcement
PU
2019SINO BIOPHARMACEUTICAL LIMITED : Ex-dividend day for quarterly dividend
FA
More news
News in other languages on SINO BIOPHARMACEUTICAL LIM
01/25NACH DEM TEILABKOMMEN IM HANDELSSTRE : Startet China jetzt durch?
2019SINO BIOPHARMACEUTICAL LIMITED : Ex-dividend day for quarterly dividend
2019SINO BIOPHARMACEUTICAL LIMITED : Ex-dividend day for quarterly dividend
2019SINO BIOPHARMACEUTICAL LIMITED : Ex-dividend day for quarterly dividend
2019SINO BIOPHARMACEUTICAL LIMITED : Ex-dividend day for final dividend
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIM
More recommendations
Sector news : Pharmaceuticals - NEC
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart SINO BIOPHARMACEUTICAL LIM
Duration : Period :
Sino Biopharmaceutical Lim Technical Analysis Chart | 1177 | KYG8167W1380 | MarketScreener
Technical analysis trends SINO BIOPHARMACEUTICAL LIM
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 12,57  HKD
Last Close Price 11,28  HKD
Spread / Highest target 47,2%
Spread / Average Target 11,4%
Spread / Lowest Target -15,8%
EPS Revisions
Managers
NameTitle
Ping Tse Chief Executive Officer & Executive Director
Y Y Tse Chairman
Hsuan Tse General Manager-Information Management
Wei Nong Ye General Manager-Research & Development
Hsin Tse Executive Director & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SINO BIOPHARMACEUTICAL LIMITED-2.88%18 179
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679